Molecular Biomarkers for the Evaluation of Colorectal Cancer

Document Type

Journal Article

Publication Date

3-1-2017

Journal

American Journal of Clinical Pathology

Volume

147

Issue

3

DOI

10.1093/ajcp/aqw209

Keywords

gastrointestinal; genetics; histology; Molecular diagnostics; oncology

Abstract

© American Society for Clinical Pathology, 2017. All rights reserved. Objectives: To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods: The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results: Twenty-one guideline statements were established. Conclusions: Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.

This document is currently not available here.

Share

COinS